Evogene (EVGN) Equity Average (2018 - 2024)
Historic Equity Average for Evogene (EVGN) over the last 7 years, with Q4 2024 value amounting to -$2.9 million.
- Evogene's Equity Average fell 11895.76% to -$2.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$2.9 million, marking a year-over-year decrease of 11895.76%. This contributed to the annual value of $5.3 million for FY2024, which is 7348.37% down from last year.
- As of Q4 2024, Evogene's Equity Average stood at -$2.9 million, which was down 11895.76% from -$638000.0 recorded in Q3 2024.
- In the past 5 years, Evogene's Equity Average ranged from a high of $69.0 million in Q2 2021 and a low of -$2.9 million during Q4 2024
- For the 5-year period, Evogene's Equity Average averaged around $30.6 million, with its median value being $28.6 million (2020).
- Per our database at Business Quant, Evogene's Equity Average soared by 10504.06% in 2021 and then plummeted by 11895.76% in 2024.
- Evogene's Equity Average (Quarter) stood at $27.9 million in 2020, then surged by 105.04% to $57.2 million in 2021, then tumbled by 48.83% to $29.3 million in 2022, then plummeted by 47.76% to $15.3 million in 2023, then crashed by 118.96% to -$2.9 million in 2024.
- Its Equity Average was -$2.9 million in Q4 2024, compared to -$638000.0 in Q3 2024 and $5.7 million in Q2 2024.